Schonfeld Strategic Advisors LLC Acquires 8,419,781 Shares of Applied Therapeutics, Inc. (NASDAQ:APLT)

Schonfeld Strategic Advisors LLC lifted its stake in shares of Applied Therapeutics, Inc. (NASDAQ:APLT - Free Report) by 2,458.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 8,762,291 shares of the company's stock after buying an additional 8,419,781 shares during the period. Schonfeld Strategic Advisors LLC owned approximately 7.53% of Applied Therapeutics worth $7,502,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of APLT. T. Rowe Price Investment Management Inc. raised its position in Applied Therapeutics by 2,511.9% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 5,420,920 shares of the company's stock valued at $4,642,000 after purchasing an additional 5,213,370 shares during the period. Propel Bio Management LLC raised its stake in shares of Applied Therapeutics by 46.4% during the 4th quarter. Propel Bio Management LLC now owns 9,615,420 shares of the company's stock worth $8,233,000 after buying an additional 3,047,562 shares during the last quarter. Marshall Wace LLP raised its position in shares of Applied Therapeutics by 144.8% in the fourth quarter. Marshall Wace LLP now owns 1,307,381 shares of the company's stock valued at $1,124,000 after buying an additional 773,377 shares during the last quarter. Norges Bank purchased a new position in Applied Therapeutics in the 4th quarter worth approximately $208,000. Finally, Rock Springs Capital Management LP boosted its holdings in Applied Therapeutics by 9.8% in the fourth quarter. Rock Springs Capital Management LP now owns 1,917,191 shares of the company's stock worth $1,641,000 after purchasing an additional 170,742 shares during the period. Hedge funds and other institutional investors own 98.31% of the company's stock.

Applied Therapeutics Stock Down 0.5 %

Applied Therapeutics stock traded down $0.00 during mid-day trading on Wednesday, hitting $0.41. The company's stock had a trading volume of 382,992 shares, compared to its average volume of 3,199,255. The stock's fifty day moving average price is $0.44 and its two-hundred day moving average price is $2.37. Applied Therapeutics, Inc. has a twelve month low of $0.30 and a twelve month high of $10.62. The stock has a market capitalization of $57.34 million, a P/E ratio of -0.25 and a beta of 2.00.

Applied Therapeutics (NASDAQ:APLT - Get Free Report) last issued its quarterly earnings results on Monday, April 14th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.06). The business had revenue of $0.00 million during the quarter, compared to the consensus estimate of $0.61 million. Equities analysts expect that Applied Therapeutics, Inc. will post -0.65 earnings per share for the current year.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.